An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2017
At a glance
- Drugs RG 7386 (Primary)
- Indications Solid tumours
- Focus First in man; Therapeutic Use
- Sponsors Roche
- 20 Jul 2017 Planned End Date changed from 26 Sep 2017 to 31 Aug 2019.
- 20 Jul 2017 Planned primary completion date changed from 26 Sep 2017 to 30 Jun 2019.
- 02 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.